What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Radiopharmaceuticals

• Publication date

  2013-05-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1874471011306020006PMID 23745775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptide imaging with somatostatin analogues: more than cancer probes.

  2013cited by this paper
• 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type

  2013cited by this paper
• Bone metastases radiopharmaceuticals: an overview.

  2013cited by this paper
• Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

  2013cited by this paper
• Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Correlation between Calcitonin Levels and [18F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer

  2012cited by this paper
• Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT

  2012cited by this paper
• 18F‐FDG‐PET and 18F‐FDG‐PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta‐analysis

  2012cited by this paper
• Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis

  2012cited by this paper
• Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.

  2012cited by this paper
• Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma

  2012cited by this paper
• Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment).

  2012cited by this paper
• [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].

  2012cited by this paper
• Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

  2012cited by this paper
• Impact of 18F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma

  2011cited by this paper
• Diagnosis of bone metastasis: recent comparative studies of imaging modalities.

  2011cited by this paper
• Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid Cancer

  2011influential reference
• Targeting Somatostatin Receptors: Preclinical Evaluation of Novel 18F-Fluoroethyltriazole-Tyr3-Octreotate Analogs for PET

  2011cited by this paper
• The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.

  2011cited by this paper
• Clinical Value of 18-Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma

  2010influential reference
• Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer

  2010cited by this paper
• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor

  2010cited by this paper
• The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).

  2010cited by this paper
• The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

  2010cited by this paper
• Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

  2010influential reference
• Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.

  2010cited by this paper
• The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT

  2009influential reference
• Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations

  2009cited by this paper
• Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

  2009cited by this paper
• Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma

  2009cited by this paper
• The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.

  2008cited by this paper
• 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation

  2008influential reference
• Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

  2007cited by this paper
• Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.

  2007cited by this paper
• 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

  2007cited by this paper
• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT

  2007cited by this paper
• Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

  2007influential reference
• Impact de la TEP à la fluoro-(18F)-dihydroxyphénylalanine (FDOPA) sur l'attitude thérapeutique en cas de tumeur endocrine : tumeur digestive, cancer médullaire de la thyroïde ou phéochromocytome

  2006cited by this paper
• Safety of 18F-DOPA injection for PET of carcinoid tumor.

  2006cited by this paper
• The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

  2006cited by this paper
• Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.

  2005cited by this paper
• Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer

  2004cited by this paper
• 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature

  2004cited by this paper
• 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

  2002cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study

  2001cited by this paper
• 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels

  2001cited by this paper
• The value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with medullary thyroid cancer

  2000cited by this paper
• The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.

  2000cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

  1999cited by this paper
• Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours

  1997cited by this paper
• Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.

  1997cited by this paper
• Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma

  1997cited by this paper

• 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography (FCH PET/CT) Imaging for Detecting Abnormal Parathyroid Glands: Indication, Practice, Interpretation and Diagnostic Performance.

  2024cites this paper
• Update on the Role of [18F]FDOPA PET/CT.

  2024cites this paper
• The role of [18F]F-DOPA PET/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients

  2024cites this paper
• The Role of 18F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels

  2023cites this paper
• Acetate-Mediated Odorant Receptor OR51E2 Activation Results in Calcitonin Secretion in Parafollicular C-Cells: A Novel Diagnostic Target of Human Medullary Thyroid Cancer

  2023cites this paper
• [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial

  2022cites this paper
• Positron Emission Tomography/Computed Tomography in Thyroid Cancer.

  2022cites this paper
• Prospective study on the clinical relevance of 18F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma

  2022cites this paper
• Role of PET/Computed Tomography in Elderly Thyroid Cancer: Tumor Biology and Clinical Management.

  2022cites this paper
• Updated Review of Nuclear Molecular Imaging of Thyroid Cancers.

  2021cites this paper
• (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer

  2020cites this paper
• Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors

  2019cites this paper
• Non-FDG Radiopharmaceuticals in Head and Neck PET Imaging: Current Techniques and Future Directions.

  2019cites this paper
• 18F-DOPA

  2019cites this paper
• Novel PET tracers: added value for endocrine disorders

  2019cites this paper
• Cancer médullaire de la thyroïde

  2018cites this paper
• Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes

  2018cites this paper
• PET imaging for thyroid cancers: Current status and future directions.

  2017cites this paper
• Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

  2017cites this paper
• Radionuclide Imaging of Medullary Thyroid Carcinoma

  2017cites this paper
• The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values

  2017cites this paper
• Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid

  2017cites this paper
• SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

  2017cites this paper
• Nuclear Medicine Techniques

  2016cites this paper
• The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels

  2016cites this paper
• 18F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma

  2016cites this paper
• Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.

  2016cites this paper
• Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma : the B evidence-based ^ refusal to endorse them by EANM due to the B not evidence-based ^ marginalization of the role of Nuclear Medicine

  2016cites this paper
• Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

  2016cites this paper
• Integrated Imaging of Thyroid Disease

  2016cites this paper
• Continued rapid growth in (68) Ga applications: update 2013 to June 2014.

  2015cites this paper
• The alpha2C-adrenoceptor as a neuropsychiatric drug tar-get - PET studies in human subjects

  2015cites this paper
• PET imaging with 68gallium labelled somatostatin analogues in the evaluation of neuroendocrine tumours (NETs)

  2015cites this paper
• Exploring the role of technitium-99m dimercaptosuccinyl acid (V) scan in medullary carcinoma thyroid patients with postoperative persistent hypercalcitoninemia in the era of positron emission tomography-computerized tomography

  2014cites this paper
• Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.

  2014cites this paper
• 18F-DOPA and 18F-FDG PET/CT, scintigraphic localization and radioguided surgery of recurrent medullary thyroid cancer: two case reports.

  2014cites this paper
• La médecine nucléaire en 2013 et les tumeurs neuroendocrines (TNE) : un choix de plus en plus personnalisé de radiopharmaceutiques

  2013cites this paper